Skip to main content

Table 6 G6PDd prevalence and primaquine policy

From: Malaria in Brazil, Colombia, Peru and Venezuela: current challenges in malaria control and elimination

Country Estimated G6PDd for common variants (mostly A −) PQ use PQ as DOT? G6PD testing required for PQ administration
Brazil >3–7% [132]
0–12.9% [133]
P. falciparum and P. vivax No No-currently under consideration and expected to be recommended when possible with follow-up of possible PQ-induced haemolysis G6PDd cases to be treated with PQ at 0.75 mg/kg/week for 8 weeks
Colombia >3–7% [132]
1.4–15.4% [133]
6.56% [135]
P. vivax No No
Peru >0–1% [132]
0–0.7% [133]
P. falciparum (since 2015) and P. vivax Yes No
Venezuela >7–10% [132]
0–3.5% [133]
3.6% [134]
P. falciparum and P. vivax No No
  1. PQ and G6PD testing policies taken from [1]
  2. P. vivax: Plasmodium vivax; P. falciparum: Plasmodium falciparum; DOT: directly observed treatment; PQ: primaquine. PQ is contraindicated in infants and pregnant and breastfeeding women